RxDoctor Payments Data

Ahmad Abazid, MD

Family Medicine · Richardson, TXNPI 1013238401

Payments from drug & device makers

$72,919in general payments, 2019–2025

Across 23 payments — averaging $3170.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$72K
  • Lilly USA, LLC$256
  • Amgen$113
  • Exact Sciences$46
  • AstraZeneca$41
  • Tolmar, Inc.$23
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,919 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,076,640
Medicare patients
78
Services billed
2,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$107,405
OzempicSemaglutide95$105,773
MounjaroTirzepatide42$43,443
JanuviaSitagliptin Phosphate54$38,085
EliquisApixaban49$35,898
RybelsusSemaglutide28$33,744
FarxigaDapagliflozin Propanediol38$30,410
TrulicityDulaglutide24$22,378
LinzessLinaclotide11$12,631
Fiasp FlextouchInsulin Aspart (Niacinamide)17$12,500
EntrestoSacubitril/Valsartan16$11,563
SynjardyEmpagliflozin/Metformin Hcl13$10,736
XareltoRivaroxaban12$10,626
Tresiba Flextouch U-100Insulin Degludec18$7,470
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$4,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$256$65,82166 claims
AstraZenecaFarxiga$41$30,41038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →